FIELD: medicine.
SUBSTANCE: present invention relates to the medicine, in particular, to the acute lymphoblastic leukemia (ALL) in children treatment, strength reduction or elimination method, including the blinatumomab administration.
EFFECT: disclosed is the acute lymphoblastic leukemia in children treatment, strength reduction or elimination method.
5 cl, 5 dwg, 4 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN | 2009 |
|
RU2536933C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | 2018 |
|
RU2736802C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA | 2009 |
|
RU2536940C2 |
| DOSE SCHEDULE FOR ADMINISTERING CD19×CD3 BISPECIFIC ANTIBODY | 2010 |
|
RU2548746C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| METHODS OF MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA TREATMENT BY T-CELL THERAPY | 2016 |
|
RU2743381C2 |
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
| COMBINATION THERAPY WITH ANTI-CD19 ANTIBODY AND A PURINE ANALOG | 2012 |
|
RU2664462C9 |
| METHODS FOR DIAGNOSING AND INDUCING LEUKAEMIA/LYMPHOMA | 2010 |
|
RU2574987C2 |
| METHOD OF TREATING RECURRENT ACUTE MYELOID LEUKAEMIA FOLLOWING TRANSPLANTATION OF ALLOGENIC HAEMOPOIETIC STEM CELLS | 2013 |
|
RU2538799C1 |
